Profil
Rebecca Cohen is currently working as an Investor Relations Contact at Ikena Oncology, Inc. Previously, she worked as the Head-Corporate & Investor Relations at SQZ Biotechnologies Co. from 2017 to 2018.
She also served as an IR & Corporate Communications Contact at Epizyme, Inc.
Aktive Positionen von Rebecca Cohen
| Unternehmen | Position | Beginn |
|---|---|---|
| IKENA ONCOLOGY, INC. | Investor Relations Contact | - |
Ehemalige bekannte Positionen von Rebecca Cohen
| Unternehmen | Position | Ende |
|---|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Investor Relations Contact | 01.07.2018 |
| EPIZYME, INC. | Public Communications Contact | 01.05.2016 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
| IKENA ONCOLOGY, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
